Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Jul 13;109(2):617–621. doi: 10.3324/haematol.2023.283224

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright© 2024 Ferrata Storti Foundation

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License (by-nc 4.0) which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

PMC Copyright notice

Figure 2. — Patients outcome. (A) Kaplan-Meier estimates of overall survival (OS) in the intention-to-treat population stratified by whether patients received a pharmacoscopy-derived treatment regimen (17 screening instances) or a regimen based on in-house guidelines (13 screening instances). (B) Kaplan-Meier estimates of event-free survival (EFS) in the intention-to-treat population stratified by whether patients received a pharmacoscopy-derived treatment regimen or not (17 vs. 13 screening instances). (C) Kaplan-Meier estimates of OS in the intention-to-treat population stratified by the ex vivo blast reduction capacity of their respective treatment regimen (integrated peritoneal cancer index [i-PCY] score) (14 screening instances with above median i-PCY score and 16 below). (D) Kaplan-Meier estimates of EFS in the intention-to-treat population stratified by the i-PCY score of their respective treatment regimen (14 vs. 16 screening instances). (E) Kaplan-Meier estimates of OS in patients receiving an acute myeloid leukemia (AML)-specific therapy (excluding patients receiving best supportive care) stratified by the i-PCY score of their respective treatment regimen (12 screening instances with above median i-PCY score and 14 below). (F) Kaplan-Meier estimates of EFS in patients receiving an AML-specific therapy stratified by the i-PCY score of their respective treatment regimen (12 vs. 14 screening instances). All P values were calculated by Gehan-Breslow-Wilcoxon test. CI: confidence interval; NS: not significant.